arrow_back Civic Audit
Share share

Limiting FDA Innovation Funds for Fiscal Year 2024

This bill proposes to limit the funds available to the Food and Drug Administration (FDA) for innovation in fiscal year 2024. This means less money will be allocated for the development of new drugs and medical technologies, potentially affecting the speed of market introduction and availability of new therapies for citizens.
Key points
The bill caps funds for the FDA Innovation Account at $50 million for fiscal year 2024.
Reduced funding may slow down research and development of new drugs and medical technologies.
article Official text account_balance Process page notifications_active Track this Bill
gavel
Status:
Expired
Record your position for audit.
Why does your vote on bills matter?
It creates raw, undeniable proof. Civic Will provides the permanent data to verify the Government's loyalty towards its citizens (explained here). Start recording it now.
Additional Information
Print number: 118_HR_2297
Sponsor: Rep. Biggs, Andy [R-AZ-5]
Process start date: 2023-03-29
System Note: Lustra is free, publicly auditable civic infrastructure, with full source code available on GitHub. You are reading sterilized legislative data, processed by our radical neutrality engine to strip political spin and retain factual mechanics. We process only official government data. Original documents remain the authoritative source, always verify them if you can.
Summarized by: gemini-2.5-flash-preview-05-20
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

To provide for a limitation on availability of funds for Related Agency and Food and Drug Administration, FDA Innovation Account, Cures Act for fiscal year 2024.

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 118_HR_2297.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2023-03-29.

What are the main provisions?

Key points include:

  • The bill caps funds for the FDA Innovation Account at $50 million for fiscal year 2024.
  • Reduced funding may slow down research and development of new drugs and medical technologies.
What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Rep. Biggs, Andy [R-AZ-5].

What is the latest detailed status?

The latest detailed status is: Referred to the Subcommittee on Health.

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-24.

What is the impact of this bill?

We don't know, that is up to you to decide. Summarizing raw data with AI is fundamentally different from predicting socio-economic outcomes. As of 2026, we believe impact assessment strictly requires a human in the loop to verify and judge.

CATEGORIES

Health Public Investments